We hypothesized that differences in active treatment rates may exist according race/ethnicity in favorable, as well as unfavorable intermediate risk (IR) prostate cancer (PCa).
We relied on the Surveillance, Epidemiology and End Results (SEER) 18 database 2010-2015.